SCHEMBL4336829

SCHEMBL4336829

CCOCCNC(=O)c1ccc2[nH]nc(-c3cc4ccccc4o3)c2c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
HSD17B10 Q99714 6/20 0.43
ALDH1A1 P00352 6/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
JAK2 O60674 2/20 0.42
JAK3 P52333 2/20 0.42
MKNK1 Q9BUB5 2/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334565 0.87 LMNA (0.41) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1
SCHEMBL2866722 0.84 GSK3B (0.41) JAK2JAK3DRD2
SCHEMBL4341547 0.84 BRD4 (0.46) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1
SCHEMBL4331216 0.84 JAK2 (0.39) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1
SCHEMBL4331810 0.83 KDR (0.42) KDM4EALDH1A1SMN1; SMN2MAPK1JAK2
SCHEMBL4341426 0.83 GAA (0.50) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1
SCHEMBL2862928 0.82 PIP5K1C (0.46) KDM4EHSD17B10ALDH1A1MEN1HTT
SCHEMBL4331838 0.82 HPGD (0.53) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1
SCHEMBL4343252 0.82 HSD17B10 (0.49) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1
SCHEMBL4327612 0.82 JAK2 (0.40) KDM4EHSD17B10ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 KDM4E 2531/4885HSD17B10 1699/4885ALDH1A1 1588/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 KDM4E 2531/4885HSD17B10 1699/4885ALDH1A1 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.